Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

Provided By PR Newswire

Last update: May 31, 2023

TORRANCE, Calif., May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.